Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Neoplasma ; 47(4): 234-8, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11043828

RESUMEN

Chromosomal aberrations (CAs), sister chromatid exchanges (SCEs) and high frequency cells (HFCs) have been assessed in peripheral blood lymphocytes of 10 neurofibromatosis (NF1) patients and 10 healthy controls. In both groups, the spontaneous rates and the induced (bleomycin for CA and MMC for SCE) frequencies were analyzed. No differences between cells from NF1 patients and controls were observed with respect to spontaneous or bleomycin induced CA. Spontaneous or MMC induced SCE frequencies were also similar in NF1 patients and controls. HFCs, on the contrary, were statistically lower in NF1 patients.


Asunto(s)
Aberraciones Cromosómicas , Neurofibromatosis 1/genética , Intercambio de Cromátides Hermanas , Adolescente , Antimetabolitos Antineoplásicos/toxicidad , Bleomicina/toxicidad , Niño , Preescolar , Fragilidad Cromosómica , Femenino , Humanos , Lactante , Masculino , Mitomicina/toxicidad , Neurofibromatosis 1/sangre , Neurofibromatosis 1/patología , Inhibidores de la Síntesis del Ácido Nucleico/toxicidad , Intercambio de Cromátides Hermanas/efectos de los fármacos
2.
Minerva Pediatr ; 44(1-2): 47-50, 1992.
Artículo en Italiano | MEDLINE | ID: mdl-1552877

RESUMEN

The Authors describe the growth of a 2 year old child affected by Dubowitz syndrome. The child came to their observation because of short stature and microcephaly.


Asunto(s)
Antropometría , Trastornos del Crecimiento/fisiopatología , Microcefalia/fisiopatología , Preescolar , Femenino , Humanos , Síndrome
3.
Minerva Pediatr ; 44(1-2): 41-2, 1992.
Artículo en Italiano | MEDLINE | ID: mdl-1552875

RESUMEN

The aim of this study was to compare growth velocity in thalassemic children using two different treatment protocols. Thalassemic children were initially treated with high daily doses of desferrioxamine, obtaining a good rate of initial growth which then unexpectedly slowed down later. The introduction of a new treatment protocol reducing both the dose and frequency with which the drug was administered provoked a significant increase in the rate of growth greater than that observed in the group treated using the previous protocol.


Asunto(s)
Terapia por Quelación , Deferoxamina/administración & dosificación , Crecimiento/efectos de los fármacos , Talasemia/fisiopatología , Talasemia/terapia , Niño , Preescolar , Deferoxamina/uso terapéutico , Femenino , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA